Experimental 1070nm Intranasal Stimulation Proof-of-Concept Study
This unit has been developed specifically to deliver 80mw of 1070nm infrared light directly into the nose to support the immune system's response to COVID-19.
There is a growing body of evidence supporting 1070nm transcranial near-infrared light photobiomodulation (tPBM) as a useful way to prevent COVID infection, reduce its virulence, and mitigate enduring post-infection neurological injury, eg., long-COVID brain fog. Quietmind Foundation has developed and is conducting an open-label case series investigation of an experimental intranasal PBM (iPBM) device designed to deliver 200mw of continuous 1070nm infrared photonic stimulation into one or both nostrils. The device can be used as a stand-alone treatment or in combination with the Neuradiant 1070 transcranial PBM technology available through Quietmind Fdn. send email to N[email protected]
We see a rapidly growing sense of urgency to identify treatment options for those struggling with long-COVID neurological symptoms (long-term-COVID prevalence) with estimates of over 200,000,000 worldwide developing serious neurological injury regardless of infection severity. QMF is responding to this crisis by testing self-administered, low-cost, safe, reliable and easily deployed technologies to help reduce COVID 19's cognitive and physiological challenges.
A proof-of-concept clinical study, (attached) supported by Quietmind Foundation's Institutional Review Board (IRB) and Neuronic Devices Ltd., conducted by Praveen Arany & Robert Bowen on Use of Either Transcranial or Whole-Body Photobiomodulation Treatments improve COVID-19 Brain Fog compared the use of the Neuradiant 1070 tPBM and the NovoThor PBM whole body stimulation bed. The study results were compelling, in that, all subjects in both treatment conditions (N=14), reported full recovery to their baseline cognitive functioning after one month of 3x weekly, 14-minute treatment sessions. These anecdotal findings were supported by highly significant neurophysiological (EEG/ERP) and neuropsychological measures including (MoCA, Trails A&B, and Digital Symbol Substitution) assessing memory, executive functioning, and processing speed. The full paper will be posted when it is made available in electronic form.
A recently published clinical trial (https://youtu.be/ZdiUnmpOgqE) showed that direct PBM stimulation to the chest produced highly significant improvement in subjects with COVID-19 symptoms. This pilot project will utilize many of the same dependent measures and endpoints and use the intranasal delivery system instead of the vest.
COVID's primary entry point is the nose making it the most effective location for mitigation. Killing the virus at this point may reduce infectivity and symptom severity. We also know our body's blood supply passes through our face every 4 minutes allowing PBM stimulation to irradiate all our blood-born mitochondria.
Users of this device are being enrolled as subjects in an ongoing open-label, uncontrolled, aggregated case series protocol. Clinical assessments using CNS Vitals may also include pre/post Quantitative EEG over 3 months of regular device usage. This project is being conducted under the auspices of the Quietmind Foundation (QMF) and monitored by QMF's Institutional Review Board.
Question regarding enrollment, please contact the principal investigator,
Marvin Berman Ph.D. at (267) 481-3987 or [email protected]
Informed consent documents and related enrollment materials will be provided when IRB approval has been obtained. Only clinicians seeking to serve as prospective research sites are welcome to purchase devices ($290) at this time. They are welcome to use the device now only to familiarize themselves with the unit's operation, assist the study coordinator in study logistics organization, and have their own personal experience.
